Cleared pathology AI reads slides that Medicare does not pay to digitize. Pathology's income exposure runs through lab ownership, two fee schedules, and a screening guideline that removes slides upstream.

In February 2025, the FDA cleared Ibex Prostate Detect, an algorithm that in Ibex's validation studies found missed cancer in 13% of a cohort of consecutive patients whose prostate biopsies had first been read as benign. The pathologist still signs the report. And as of October 2026, Medicare assigns no national payment to the digital slide the algorithm needs: the 43 add-on codes that describe digitizing glass have carried no national relative value since they were created in 2023 and 2024. Pathology has cleared AI, no national payment for the step that feeds it, and adoption under 15%. The specialty's income is exposed somewhere else.
Figures are as of October 2026 and the perishable ones will be updated.
Paige received the first FDA authorization for an AI product in digital pathology in September 2021. Ibex followed in 2025. Cleared platform and viewer systems now include PathAI's AISight Dx, PathPresenter's clinical viewer and Roche's digital pathology scanner. Each is cleared as an aid to a pathologist who renders the diagnosis. In the 2024 ASCP vacancy survey, 17.4% of laboratories reported using AI tools at all, nearly three-quarters did not expect AI to change their hiring qualifications, and most reported no staffing changes from it. Where labs use AI, most adoption clusters in laboratory information systems, quality-assurance workflows and anatomic pathology.
The constraint is upstream of the algorithm. An AI reads a digital image, and a digital image requires scanning the glass, which requires scanners, storage and staff. CAP secured 13 Category III add-on codes for digitization in 2023 and 30 more in 2024. As of 2026 none carries a national payment rate; Medicare contractors variously allow them for data collection only or set local rates, and under the hospital outpatient system they are packaged into the primary service. Digitization is a pure cost, so a laboratory adopts it only where it displaces labor it already pays for. The tool that arrives first is the one that lets a lab do the same work with fewer technologists and, later, with fewer reads per pathologist.
From the surgeon's side, final margins reach me in three to seven days, depending on the type of cancer, as a pathology report and sometimes a call from the pathologist. A same-day digital read, once its accuracy was proven equivalent, would allow more same-day reconstructions instead of staging them while the margins come back. It would work like Mohs, but with permanent staining rather than frozen sections, higher accuracy, and coverage of more types of cancer, which could help most with sarcomas and other cancers that are harder to read. For both ablative and reconstructive surgery that would be huge. The bottlenecks are preparation and staining time, and how quickly a pathologist can get to the case.
On December 4, 2025, the American Cancer Society made primary HPV testing every five years the preferred cervical screening strategy for ages 25 to 65, accepted self-collected vaginal specimens, and demoted cytology alone to a fallback every three years. The U.S. Preventive Services Task Force has a draft in the same direction. Self-collection removes the clinician visit and the cytology slide together. No one has quantified the workforce effect; the cytopathology consortium's comment letter says labs will need several years to transition and stops there.
The counterweight is complexity. Case volumes, molecular testing and the workup of benign lesions found by broader screening are all rising, and a March 2026 CMAJ analysis of the Canadian workforce argues that pathologist supply has not kept pace with them. The work per case is going up while one high-volume, low-complexity case type is being designed out.
Pathologists control none of their own volume. Surgeons, dermatologists, gastroenterologists and gynecologists generate it, and the variable that decides which pathologist reads it is who holds the laboratory contract. That is consolidating. Labcorp reported $13.95 billion of revenue for 2025, up 7.2%, of which 2.5 points came from acquisitions net of divestitures. In the fourth quarter it completed purchases of Community Health Systems' outreach laboratory assets and Incyte Diagnostics' anatomic pathology assets and agreed to buy Parkview Health's outreach laboratory services. Each transaction converts an independent or hospital-employed group's book of business into a national laboratory's, and the pathologist who read those cases becomes, or is replaced by, an employee of the acquirer.
Pathologists' assistants gross and dissect specimens under supervision. The binding constraint in the laboratory is technical staff. The ASCP's December 2025 report on its 2024 vacancy survey cites Bureau of Labor Statistics projections of more than 24,000 laboratory openings a year against about 8,800 graduates of training programs, and many departments need three months to a year to fill a position. A lab that cannot hire technologists has a direct case for automating the bench, and bench automation is where digitization pays for itself first.
Pathology is paid on two fee schedules, and conflating them is the commonest error in coverage of the specialty. The pathologist's professional work is paid on the physician fee schedule. The laboratory tests are paid on the Clinical Laboratory Fee Schedule under the Protecting Access to Medicare Act, whose first data-collection round produced nearly $4 billion in cuts. Congress has delayed the reporting requirement seven times and the cuts six; the latest deferral, in the appropriations act signed February 3, 2026, averted cuts of up to 15% on about 800 tests for 2026. Reporting resumed in May 2026, and on September 21, 2026, CMS published preliminary 2027 rates that would lower payment for 1,171 test codes, with any single cut capped at 15% a year through 2029. The final rates are due in November and take effect January 1, 2027, unless Congress acts again. A permanent fix that would substitute commercial-payer data for laboratory self-reporting has been introduced and not enacted.
On the physician side, 2026 was a net +0.5% for pathology. The 2.5% efficiency adjustment applied to 91% of physician services and exempted only time-based, maternity, telehealth and new codes; CMS declined ASCP's request to exempt the clinical consultation codes. Pathology's codes are not time-based, so the specialty absorbed the cut almost in full, and the practice-expense reallocation in the same rule raised measured costs for office-based practices. The efficiency adjustment recurs every three years by CMS's stated intent.
The widely cited finding that the U.S. pathologist workforce shrank sharply between 2007 and 2017 comes from a 2019 JAMA Network Open study of the AMA Masterfile. A 2020 follow-up in the same journal found the Masterfile undercounts pathologists by about 40%, roughly 8,000 physicians, because a pathologist who completes a subspecialty fellowship has their primary specialty overwritten, and 97% of residents now take one. HRSA's December 2025 projection still puts pathology at 84% of demand in 2038, a shortage, and the 2026 Match filled 99.7% of positions. Burnout, at 28.3%, is among the lowest of any specialty. The specialty is short and slow to grow: PGY-1 positions rose 10% in a decade in which internal medicine's rose 59%.
The replacement question turns on a payment rate that does not exist yet. Until Medicare pays for the digital slide, AI in pathology spreads where it cuts bench labor, and the pathologist's read is the last step to be touched. The exposure that is live today runs through the lab contract, which decides who reads the case; the laboratory fee schedule, which Congress re-freezes every year or two; the physician fee schedule's efficiency adjustment, which the specialty absorbs in full; and a screening guideline that removes slides before they are cut. The Specialty Exposure Map scores those inputs for pathology alongside the other specialties on the map.
A pathologist employed by a health system or a national laboratory is paid a share of a professional fee that the efficiency adjustment lowers on a schedule. One who holds a stake in an independent laboratory owns the contract that the acquirers above are buying. Why the professional fee falls while the work rises is here.
The Income Variable uses pathology as the case where the technology arrived before the payment did, and works through what a specialty's plan looks like when the substitution channel is real but controlled by a code CMS has not valued. The second part of the book covers the ownership forms that put a physician on the buying side of a laboratory rather than the sold side. Join the launch list for the book and the free companion tools.
This article is general information and analysis, not individualized medical, financial, investment, tax, or legal advice. See the Disclaimers page for the full statement.
Double board-certified reconstructive surgeon in Austin, Texas. Author of The Income Variable.
About the author
Join the launch list for book updates, new articles, and free companion tools.
By submitting, you agree to our Terms of Use and acknowledge our Privacy Policy.